conclusions
Last reviewed 01/2018
Single agent carboplatin or CAP are as effective as carboplatin plus paclitaxel in the treatment of ovarian cancer.
The better side-effect profile of carboplatin alone makes it a reasonable first-line chemotherapeutic agent for ovarian cancer.